FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133053> ?p ?o ?g. }

• W4308133053 endingPage "A781" @default.
• W4308133053 startingPage "A780" @default.
• W4308133053 abstract "Abstract Background Thyroiditis and Graves’ disease have been reported after COVID-19 vaccination. Patients with hypothyroidism due to various etiologies may be at risk of thyroid-specific outcomes. We aimed to evaluate the risks of thyroid-specific outcomes and adverse events after COVID-19 vaccination among patients treated for hypothyroidism. Methods In this population-based cohort from Hong Kong Hospital Authority electronic health records with Department of Health vaccination records linkage, levothyroxine users were categorized into unvaccinated, vaccinated with BNT162b2 (mRNA vaccine) or CoronaVac (inactivated vaccine) between 23 February and 9 September 2021. Propensity score (PS) weighting with inverse probability of treatment weighting (IPTW) was applied to balance the baseline characteristics among the three groups, which included age, sex, history of COVID-19, health care utilization, comorbidities, baseline thyroid-stimulating hormone (TSH) level (within the 6 months before the index date), and recent use of medications including anti-hypertensive, anti-diabetic and lipid-lowering agents. Study outcomes were dosage reduction or escalation in levothyroxine, emergency department visit, unscheduled hospitalization, adverse events of special interest (AESI) according to World Health Organization's Global Advisory Committee on Vaccine Safety, and all-cause mortality. Results In total, 47,086 levothyroxine users were identified (BNT162b2: n=12,310; CoronaVac: n=11,353; unvaccinated: n=23,423). After PS weighting, all baseline characteristics had standardised differences of less than 0.2, implying a balance of covariates among the three groups. COVID-19 vaccination was not associated with increased risks of levothyroxine dosage reduction (BNT162b2: HR=0.971, 95% CI 0.892–1. 058; CoronaVac: HR=0.968, 95% CI 0.904–1. 037) or escalation (BNT162b2: HR=0.779, 95% CI 0.519–1.169; CoronaVac: HR=0.715, 95% CI 0.481–1. 062). Besides, COVID-19 vaccination was not associated with a higher risk of emergency department visits (BNT162b2: HR=0.944, 95% CI 0.700-1.273; CoronaVac: HR=0.851, 95% CI 0.647-1.120) or unscheduled hospitalization (BNT162b2: HR=0.905, 95% CI 0.539-1.520; CoronaVac: HR=0.735, 95% CI 0.448-1.207). There were two (0. 016%) deaths and six (0. 062%) AESI recorded for BNT162b2 recipients, and one (0. 009%) and three (0. 035%) for CoronaVac recipients, respectively. Sensitivity analyses were performed by stratifying the groups according to age, sex and pre-vaccination thyroid status. The results were largely consistent with the main analysis. Conclusion BNT162b2 or CoronaVac vaccination is not associated with unstable thyroid status or an increased risk of adverse outcomes among patients treated for hypothyroidism. These reassuring data should encourage them to get vaccinated against COVID-19 for protection from potentially worse COVID-19-related outcomes. Presentation: No date and time listed" @default.
• W4308133053 created "2022-11-08" @default.
• W4308133053 creator A5002297351 @default.
• W4308133053 creator A5005467590 @default.
• W4308133053 creator A5011255175 @default.
• W4308133053 creator A5012652576 @default.
• W4308133053 creator A5015891056 @default.
• W4308133053 creator A5016334509 @default.
• W4308133053 creator A5020683581 @default.
• W4308133053 creator A5025936391 @default.
• W4308133053 creator A5033684035 @default.
• W4308133053 creator A5036841274 @default.
• W4308133053 creator A5039317388 @default.
• W4308133053 creator A5041610413 @default.
• W4308133053 creator A5043051253 @default.
• W4308133053 creator A5079729727 @default.
• W4308133053 date "2022-11-01" @default.
• W4308133053 modified "2023-09-30" @default.
• W4308133053 title "ODP514 Safety of Inactivated and mRNA COVID-19 Vaccination among Patients Treated for Hypothyroidism: a Population-based Cohort Study" @default.
• W4308133053 doi "https://doi.org/10.1210/jendso/bvac150.1614" @default.
• W4308133053 hasPublicationYear "2022" @default.
• W4308133053 type Work @default.
• W4308133053 citedByCount "1" @default.
• W4308133053 countsByYear W43081330532023 @default.
• W4308133053 crossrefType "journal-article" @default.
• W4308133053 hasAuthorship W4308133053A5002297351 @default.
• W4308133053 hasAuthorship W4308133053A5005467590 @default.
• W4308133053 hasAuthorship W4308133053A5011255175 @default.
• W4308133053 hasAuthorship W4308133053A5012652576 @default.
• W4308133053 hasAuthorship W4308133053A5015891056 @default.
• W4308133053 hasAuthorship W4308133053A5016334509 @default.
• W4308133053 hasAuthorship W4308133053A5020683581 @default.
• W4308133053 hasAuthorship W4308133053A5025936391 @default.
• W4308133053 hasAuthorship W4308133053A5033684035 @default.
• W4308133053 hasAuthorship W4308133053A5036841274 @default.
• W4308133053 hasAuthorship W4308133053A5039317388 @default.
• W4308133053 hasAuthorship W4308133053A5041610413 @default.
• W4308133053 hasAuthorship W4308133053A5043051253 @default.
• W4308133053 hasAuthorship W4308133053A5079729727 @default.
• W4308133053 hasBestOaLocation W43081330531 @default.
• W4308133053 hasConcept C126322002 @default.
• W4308133053 hasConcept C187212893 @default.
• W4308133053 hasConcept C194828623 @default.
• W4308133053 hasConcept C197934379 @default.
• W4308133053 hasConcept C203014093 @default.
• W4308133053 hasConcept C22070199 @default.
• W4308133053 hasConcept C2775883008 @default.
• W4308133053 hasConcept C2908647359 @default.
• W4308133053 hasConcept C526584372 @default.
• W4308133053 hasConcept C71924100 @default.
• W4308133053 hasConcept C72563966 @default.
• W4308133053 hasConcept C99454951 @default.
• W4308133053 hasConceptScore W4308133053C126322002 @default.
• W4308133053 hasConceptScore W4308133053C187212893 @default.
• W4308133053 hasConceptScore W4308133053C194828623 @default.
• W4308133053 hasConceptScore W4308133053C197934379 @default.
• W4308133053 hasConceptScore W4308133053C203014093 @default.
• W4308133053 hasConceptScore W4308133053C22070199 @default.
• W4308133053 hasConceptScore W4308133053C2775883008 @default.
• W4308133053 hasConceptScore W4308133053C2908647359 @default.
• W4308133053 hasConceptScore W4308133053C526584372 @default.
• W4308133053 hasConceptScore W4308133053C71924100 @default.
• W4308133053 hasConceptScore W4308133053C72563966 @default.
• W4308133053 hasConceptScore W4308133053C99454951 @default.
• W4308133053 hasIssue "Supplement_1" @default.
• W4308133053 hasLocation W43081330531 @default.
• W4308133053 hasLocation W43081330532 @default.
• W4308133053 hasOpenAccess W4308133053 @default.
• W4308133053 hasPrimaryLocation W43081330531 @default.
• W4308133053 hasRelatedWork W1904268084 @default.
• W4308133053 hasRelatedWork W2011960454 @default.
• W4308133053 hasRelatedWork W2315085516 @default.
• W4308133053 hasRelatedWork W2603773853 @default.
• W4308133053 hasRelatedWork W2734194671 @default.
• W4308133053 hasRelatedWork W2748952813 @default.
• W4308133053 hasRelatedWork W2954525931 @default.
• W4308133053 hasRelatedWork W3047746655 @default.
• W4308133053 hasRelatedWork W3185803516 @default.
• W4308133053 hasRelatedWork W4229045589 @default.
• W4308133053 hasVolume "6" @default.
• W4308133053 isParatext "false" @default.
• W4308133053 isRetracted "false" @default.
• W4308133053 workType "article" @default.